Vascular Effects of Carvedilol Versus Metoprolol in Hypertensive Patients With Type 2 Diabetes

Inclusion Criteria: * Age 30-80 years old * Documented history of type 2 diabetes * Stable angiotensin converting enzyme/angiotensin receptor blocker (ACE/ARB) regimen 30 days before and throughout the study period * Stable anti-diabetic regimen throughout the study period * Body mass index (BMI) between 22-45 kg/m2 * HbA1c between 6-9% for patients on anti-diabetic treatment regimen and HbA1c between 6-8% for patients who are being controlled by diet alone * Screening blood pressure (BP) \> 130/80 (average of 3 sitting measurements), with current medications Exclusion Criteria: * Uncontrollable or symptomatic arrhythmias * Unstable angina * Sick sinus syndrome or second or third degree heart block * Decompensated heart failure * Myocardial infarction (MI) or stroke within 3 months of screening * Bradycardia * Chronic obstructive pulmonary disease (COPD) with required inhaled or oral bronchodilators or corticosteroids * Bronchial asthma or related bronchospastic conditions * New onset/diagnosed type 2 diabetes (\<3 months) * Clinically significant renal or liver disease (creatinine \>2.5 mg/dL) * Endocrine disorders * Use of anorectic or other diet drugs inconsistent with recommendations for type 2 diabetics * Use of beta-blockers within 3 months of screening * Use of corticosteroids * Systemic disease, including cancer, with reduced life expectancy (\<12 months) * Psychological illness/condition that interferes with comprehension of study requirements * Use of an investigational drug within 30 days of entry into study